Circassia is beginning a Phase III trial for its short-course immunotherapy for grass allergies. This common type of allergy can significantly impact the life quality of patients.
Its therapies for allergy are based on synthetic peptide immuno-regulatory epitope class of the therapies (SPIREs).
These first-in-class compounds were designed to induce tolerance to specific allergies with a short course of treatment, by stimulating the formation of allergy-mitigating regulatory T-cells.
Now, Circassia is moving on with the clinical development of one of these treatments. It has initiated a Phase III trial for its grass allergy immunotherapy, designed to meet regulatory requirements for market access in both the US and Europe.
The trial will start by evaluating 400 patients aged 12 to 75 years old. If the results from this group of patients are favourable,